

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
18 March 2004 (18.03.2004)

PCT

(10) International Publication Number
WO 2004/022537 A2

(51) International Patent Classification⁷: **C07D 209/00**

(74) Agents: **JOHNSON, Philip, S.** et al.; Johnson & Johnson,
1 Johnson & Johnson Plaza, New Brunswick, NJ 08933
(US).

(21) International Application Number:
PCT/US2003/028017

(22) International Filing Date:
5 September 2003 (05.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/408,723 6 September 2002 (06.09.2002) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*):
JANSSEN PHARMACEUTICA, N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **CAI, Hui** [CN/US]; 11213 Corte Belleza, San Diego, CA 92130 (US). **CAR-RUTHERS, Nicholas, I.** [US/US]; 14370 Silver Heights Road, Poway, CA 92064 (US). **DVORAK, Curt, A.** [US/US]; 7657 Angeleno Road, San Diego, CA 92126 (US). **EDWARDS, James, P.** [US/US]; 8723 Hesby Court, San Diego, CA 92129 (US). **KWOK, Annette, K.** [US/US]; 10 Blanchard Street, Concord, NH 03301 (US).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HETEROCYCLIC COMPOUNDS

(57) Abstract: Certain thienopyrrolyl and furanopyrrolyl compounds are disclosed as useful to treat or prevent disorders and conditions mediated by the histamine H₄ receptor, including allergic rhinitis.



WO 2004/022537 A2

HETEROCYCLIC COMPOUNDS

Field of the Invention

The invention relates to novel, pharmaceutically active, fused
5 heterocyclic compounds and methods of using them to treat or prevent disorders and conditions mediated by the histamine H₄ receptor.

Background of the Invention

Histamine was first identified as a hormone (G. Barger and H.H. Dale, *J. Physiol. (London)* 1910, 41:19–59) and has since been demonstrated to play a
10 major role in a variety of physiological processes, including the inflammatory “triple response” via H₁ receptors (A.S.F. Ash and H.O. Schild, *Br. J. Pharmac. Chemother.* 1966, 27:427–439), gastric acid secretion via H₂ receptors (J.W. Black et al., *Nature* 1972, 236:385–390), and neurotransmitter release in the
15 central nervous system via H₃ receptors (J.-M. Arrang et al., *Nature* 1983, 302:832–837) (for review see S.J. Hill et al., *Pharmacol. Rev.* 1997, 49(3):253–278). All three histamine receptor subtypes have been demonstrated to be members of the superfamily of G protein-coupled receptors (I. Gantz et al., *Proc. Natl. Acad. Sci. U.S.A.* 1991, 88:429–433; T.W. Lovenberg et al., *Mol. Pharmacol.* 1999, 55(6):1101–1107; M. Yamashita et al., *Proc. Natl. Acad. Sci. U.S.A.* 1991, 88:11515–11519). There are, however, additional functions of histamine that have been reported, for which no receptor has been identified. For example, in 1994, Raible et al. demonstrated that histamine and R- α -methylhistamine could activate calcium mobilization in human eosinophils
25 (D.G. Raible et al., *Am. J. Respir. Crit. Care Med.* 1994, 149:1506–1511). These responses were blocked by the H₃-receptor antagonist thioperamide. However, R- α -methylhistamine was significantly less potent than histamine, which was not consistent with the involvement of known H₃ receptor subtypes. Therefore, Raible et al. hypothesized the existence of a novel histamine
30 receptor on eosinophils that was non-H₁, non-H₂, and non-H₃. Most recently several groups (T. Oda et al., *J. Biol. Chem.* 2000, 275(47):36781–36786; C. Liu et al., *Mol. Pharmacol.* 2001, 59(3):420–426; T. Nguyen et al., *Mol. Pharmacol.* 2001, 59(3):427–433; Y. Zhu et al., *Mol. Pharmacol.* 2001,

59(3):434–441; K.L. Morse et al., *J. Pharmacol. Exp. Ther.* 2001, 296(3):1058–1066) have identified and characterized a fourth histamine receptor subtype, the H₄ receptor. This receptor is a 390 amino acid, seven-transmembrane, G protein-coupled receptor with approximately 40% homology to the histamine H₃ receptor. In contrast to the H₃ receptor, which is primarily located in the brain, the H₄ receptor is expressed at greater levels in neutrophils and mast cells, among other cells, as reported by Morse et al. (see above).

Events that elicit the inflammatory response include physical stimulation (including trauma), chemical stimulation, infection, and invasion by a foreign body. The inflammatory response is characterized by pain, increased temperature, redness, swelling, reduced function, or a combination of these. Many conditions, such as allergies, asthma, chronic obstructed pulmonary disease (COPD), atherosclerosis, and autoimmune diseases, including rheumatoid arthritis and lupus, are characterized by excessive or prolonged inflammation. Inhibition of leukocyte recruitment can provide significant therapeutic value. Inflammatory diseases or inflammation-mediated diseases or conditions include, but are not limited to, acute inflammation, allergic inflammation, and chronic inflammation.


Mast cell de-granulation (exocytosis) leads to an inflammatory response that may be initially characterized by a histamine-modulated wheal and flare reaction. A wide variety of immunological (e.g., allergens or antibodies) and non-immunological (e.g., chemical) stimuli may cause the activation, recruitment, and de-granulation of mast cells. Mast cell activation initiates allergic (H₁) inflammatory responses, which in turn cause the recruitment of other effector cells that further contribute to the inflammatory response. The histamine H₂ receptors modulate gastric acid secretion, and the histamine H₃ receptors affect neurotransmitter release in the central nervous system.

Examples of textbooks on the subject of inflammation include J.I. Gallin and R. Snyderman, Inflammation: Basic Principles and Clinical Correlates, 3rd Edition, (Lippincott Williams & Wilkins, Philadelphia, 1999); V. Stvrtnova, J. Jakubovsky and I. Hulin, "Inflammation and Fever", Pathophysiology Principles of Diseases (Textbook for Medical Students, Academic Press, 1995); Cecil et


al., Textbook Of Medicine, 18th Edition (W.B. Saunders Company, 1988); and Steadmans Medical Dictionary.

SUMMARY OF THE INVENTION

5 The invention features a compound of formula (I):



wherein



10

Y is O or S;

Z is O or S;

n is 1 or 2;

m is 1 or 2;

15 n + m is 2 or 3;

R¹ is H or C₁₋₆alkyl;

R² is H, F, Cl, Br or C₁₋₆alkyl;

R³ and R⁴ are, independently, H, C₁₋₄alkyl, C₃₋₆cycloalkyl,

20 C₁₋₄alkyl(C₃₋₆cycloalkyl), cyano, -CF₃, -(CO)NR^pR^q, -(CO)OR^r, -CH₂NR^pR^q or -CH₂OR^r; where R^p, R^q and R^r are independently selected from H, C₁₋₄alkyl, C₃₋₆cycloalkyl, phenyl, -C₁₋₂alkyl(C₃₋₆cycloalkyl), benzyl or phenethyl, or R^p and R^q taken together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring with 0 or 1 additional heteroatoms selected from O, S, NH or NC₁₋₆alkyl, and where any phenyl or alkyl or cycloalkyl moiety of the foregoing is optionally and

25

independently substituted with between 1 and 3 substituents selected from C₁₋₃alkyl, halo, hydroxy, amino, and C₁₋₃alkoxy;

R⁵ and R⁶ are, independently, H or C₁₋₆alkyl;

R⁷ is -R^a, -R^bR^a, -R^e-O-R^a or -R^e-N(R^c)(R^d), where R^a is H, cyano,

5 -(C=O)N(R^c)(R^d), -C(=NH)(NH₂), C₁₋₁₀alkyl, C₂₋₈alkenyl, C₃₋₈cycloalkyl, C₄₋₇heterocyclic radical or phenyl, where the C₄₋₇heterocyclic radical is attached at a carbon atom and contains one of O, S, NH or NC₁₋₄alkyl, and optionally an additional NH or NC₁₋₆alkyl in rings of 5 or 6 or 7 members, where R^b is C₁₋₈alkylene or C₂₋₈alkenylene, where R^e is
10 C₂₋₈alkylene or C₂₋₈alkenylene, where R^c and R^d are each independently H, C₁₋₄alkyl, C₂₋₄alkenyl, C₃₋₆cycloalkyl or phenyl, or R^c and R^d taken together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring with 0 or 1 additional heteroatoms selected from O, S, NH or NC₁₋₆alkyl, and where any phenyl or alkyl or cycloalkyl
15 moiety of the foregoing is optionally and independently substituted with between 1 and 3 substituents selected from C₁₋₃alkyl, halo, hydroxy, amino, and C₁₋₃alkoxy;

alternatively, R⁷ may be taken together with an adjacent R⁴ as well as their carbon and nitrogen of attachment to form a 5, 6 or 7 membered
20 heterocyclic ring, with 0 or 1 additional heteroatoms selected from O, S, NH or NC₁₋₆alkyl, and optionally and independently substituted with between 1 and 3 substituents selected from C₁₋₃alkyl, halo, hydroxy, amino, and C₁₋₃alkoxy;

R⁸ and R⁹ are, independently, H, F, Cl, Br, I, C₁₋₄alkyl, C₁₋₄alkoxy,
25 -C₃₋₆cycloalkyl, -OC₃₋₆cycloalkyl, -OCH₂Ph, -CF₃, -OCF₃, -SCF₃, -(C=O)R^k (wherein R^k is H, C₁₋₄alkyl, -OH, phenyl, benzyl, phenethyl or C₁₋₆alkoxy), -(N-R^t)(C=O)R^k (where R^t is H or C₁₋₄alkyl), -(N-R^t)SO₂C₁₋₄alkyl, -(S(=O)_p)-C₁₋₄alkyl (wherein p is 0, 1 or 2), nitro, -SO₂NR^lR^m (wherein R^l and R^m are independently selected from H, C₁₋₄alkyl, phenyl, benzyl or phenethyl, or R^l and R^m taken together with the nitrogen to which they are
30 attached, form a 4-7 membered heterocyclic ring with 0 or 1 additional heteroatoms selected from O, S, NH or NC₁₋₄alkyl), -(C=O)NR^lR^m, cyano or phenyl, where any phenyl or alkyl or cycloalkyl moiety of the foregoing

is optionally and independently substituted with between 1 and 3 substituents selected from C₁₋₃alkyl, halo, hydroxy, amino, and C₁₋₃alkoxy; and enantiomers, diastereomers and pharmaceutically acceptable salts and esters thereof,

5 with the following provisos,

that R⁶ adjacent to N must be H where R⁴ adjacent to N is other than H,

that R⁷ is not -CH₂CH₂OH; and

that where the core molecule is a 4*H*-furo, then one of R⁴ and R⁶ adjacent to N must not be methyl when the other is hydrogen unless R⁶ and R⁴ are taken

10 together to form a bridging moiety.

The invention also features pharmaceutical compositions containing such compounds and methods of using such compositions in the treatment or prevention of H₄-mediated diseases and conditions, particularly those wherein it is desirable to antagonize the H₄ receptor.

15

DETAILED DESCRIPTION

Preferably, Y is S.

Preferably, Z is O.

Preferably, n is 1 and m is 1.

20 Preferrably, R¹ is selected from the group consisting of H or methyl.

Preferrably, R² is H.

Preferrably, R³ and R⁴ are, independently, selected from the group consisting of

a) H,

25 b) -CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH(CH₃)₂, n-butyl, i-butyl, t-butyl,

c) cyclopropyl, cyclopentyl, cyclohexyl, -CH₂cyclopropyl, -CH₂cyclopentyl, -CH₂cyclohexyl, -CH₂Ocyclopropyl, -CH₂Ocyclopentyl, -CH₂Ocyclohexyl,

d) cyano,

30 e) trifluoromethyl,

f) -(C=O)NH₂, -(C=O)NHC₁₋₄alkyl, -(C=O)N(C₁₋₄alkyl)₂, -(C=O)NHphenyl, -(C=O)pyrrolidin-1-yl, -(C=O)imidazolidin-1-yl, -(C=O)pyrazolidin-1-yl,

- (C=O)piperidin-1-yl, -(C=O)piperazin-1-yl, -(C=O)morpholin-4-yl,
 -(C=O)thiomorpholin-4-yl,
 g) -COOH, -COOCH₃, -COOCH₂CH₃, -COOphenyl, -COObenzyl,
 h) -CH₂NH₂, -CH₂NHC₁₋₄alkyl, -CH₂N(C₁₋₄alkyl)₂, -CH₂NHphenyl,
 5 -CH₂NHbenzyl, -CH₂pyrrolidin-1-yl, -CH₂imidazolidin-1-yl, -CH₂pyrazolidin-1-yl,
 -CH₂piperidin-1-yl, -CH₂piperazin-1-yl, -CH₂morpholin-4-yl,
 -CH₂thiomorpholin-4-yl,
 i) -CH₂OH, -CH₂CH₂OH, -CH₂CH₂CH₂OH, -CH₂OCH₃, -CH₂OCH₂CH₃,
 -CH₂OCH₂CH₂CH₃, -CH₂OCH(CH₃)₂, -CH₂O-n-butyl, -CH₂O-i-butyl,
 10 -CH₂O-t-butyl, -CH₂Ophenyl, -CH₂Obenzyl and -CH₂OCH₂cyclopropyl.
 Most preferably, R³ and R⁴ are, independently, H or -CH₃.
 Preferably, R⁵ and R⁶ are, independently, selected from the group
 consisting of H and methyl.
 Most preferably, R⁵ and R⁶ are H.
 15 Preferably, R⁷ is selected from the group consisting of
 a) H, -CH₂CH₂CH₂OH,
 b) cyano,
 c) -(C=O)NH₂, -(C=O)NHC₁₋₄alkyl, -(C=O)N(C₁₋₄alkyl)₂, -(C=O)NHphenyl,
 -(C=O)pyrrolidin-1-yl, -(C=O)imidazolidin-1-yl, -(C=O)pyrazolidin-1-yl,
 20 -(C=O)piperidin-1-yl, -(C=O)piperazin-1-yl, -(C=O)morpholin-4-yl,
 -(C=O)thiomorpholin-4-yl, -CH₂(C=O)NH₂, -CH₂(C=O)NHC₁₋₄alkyl,
 -CH₂(C=O)N(C₁₋₄alkyl)₂, -CH₂(C=O)NHphenyl, -CH₂(C=O)pyrrolidin-1-yl,
 -CH₂(C=O)imidazolidin-1-yl, -CH₂(C=O)pyrazolidin-1-yl,
 -CH₂(C=O)piperidin-1-yl, -CH₂(C=O)piperazin-1-yl, -CH₂(C=O)morpholin-4-yl,
 25 -CH₂(C=O)thiomorpholin-4-yl, -CH₂CH₂O(C=O)NH₂,
 -CH₂CH₂O(C=O)NHC₁₋₄alkyl, -CH₂CH₂O(C=O)N(C₁₋₄alkyl)₂,
 -CH₂CH₂O(C=O)NHphenyl, -CH₂CH₂O(C=O)pyrrolidin-1-yl,
 -CH₂CH₂O(C=O)imidazolidin-1-yl, -CH₂CH₂O(C=O)pyrazolidin-1-yl,
 -CH₂CH₂O(C=O)piperidin-1-yl, -CH₂CH₂O(C=O)piperazin-1-yl,
 30 -CH₂CH₂O(C=O)morpholin-4-yl, -CH₂CH₂O(C=O)thiomorpholin-4-yl,
 d) -C(=NH)(NH₂), -CH₂C(=NH)(NH₂),


- e) -CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH(CH₃)₂, n-butyl, i-butyl, t-butyl, -CH₂CH₂OCH₃, -CH₂CH₂OCH₂CH₃, -CH₂CH₂OCH₂CH₂CH₃, -CH₂CH₂OCH(CH₃)₂, -CH₂CH₂O-n-butyl, -CH₂CH₂O-i-butyl, -CH₂CH₂O-t-butyl, f), -CH₂CH=CH₂,
- 5 g) cyclopropyl, cyclopentyl, cyclohexyl, -CH₂cyclopropyl, -CH₂cyclopentyl, -CH₂cyclohexyl, -CH₂CH₂Ocyclopropyl, -CH₂CH₂Ocyclopentyl, -CH₂CH₂Ocyclohexyl,
- h) pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, -CH₂pyrrolidinyl, -CH₂imidazolidinyl,
- 10 -CH₂pyrazolidinyl, -CH₂piperidinyl, -CH₂piperazinyl, -CH₂morpholinyl, -CH₂thiomorpholinyl,
- i) -CH₂CH₂NH₂, -CH₂CH₂NHC₁₋₄alkyl, -CH₂CH₂N(C₁₋₄alkyl)₂, -CH₂CH₂NHphenyl, -CH₂CH₂pyrrolidin-1-yl, -CH₂CH₂imidazolidin-1-yl, -CH₂CH₂pyrazolidin-1-yl, -CH₂CH₂piperidin-1-yl, -CH₂CH₂piperazin-1-yl,
- 15 -CH₂CH₂morpholin-4-yl, -CH₂CH₂thiomorpholin-4-yl,
- j) phenyl, benzyl, phenethyl and benzyloxymethyl.
- Most preferably, R⁷ is selected from the group consisting of H and -CH₃. Preferred R⁷ taken together with an adjacent R⁴ as well as their carbon and nitrogen of attachment are pyrrolidin-1,2-yl, imidazolidin-1,2-yl,
- 20 imidazolidin-1,5-yl, pyrazolidin-1,5-yl, piperidin-1,2-yl, piperazin-1,2-yl, morpholin-4,5-yl and thiomorpholin-4,5-yl.
- Most preferred R⁷ taken together with an adjacent R⁴ as well as their carbon and nitrogen of attachment are pyrrolidin-1,2-yl and piperidin-1,2-yl.
- Preferably, R⁸ and R⁹ are, independently, selected from the group
- 25 consisting of H, -F, -Cl, -Br, -I, -CH₃, -CH₂CH₃, -OCH₃, -OCH₂CH₃, -OCH(CH₃)₂, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -Ocyclopropyl, -Ocyclohexyl, -CF₃, -OCF₃, -SCF₃, -COOH, -COOCH₃, -COOCH₂CH₃, -C(O)CH₃, -NHCOCH₃, -NCH₃COCH₃, -NH₂SO₂CH₃, -NCH₃SO₂CH₃, -SOCH₃, -SO₂CH₃, -NO₂, -SO₂NH₂, -SO₂NHCH₃, -SO₂N(CH₃)₂, -C(O)NH₂, -C(O)N(CH₃)₂, -C(O)NH(CH₃),
- 30 -CN and phenyl.

Most preferably, R⁸ and R⁹ are, independently, selected from the group consisting of hydrogen, methyl, chloro and bromo. Further, it is most preferred that one or both of R⁸ and R⁹ are not hydrogen.


The "pharmaceutically acceptable salts and esters thereof" refer to those salt and ester forms of the compounds of the present invention ~~which~~ that would be apparent to the pharmaceutical chemist, i.e., those ~~which~~ that are non-toxic and ~~which~~ that would favorably affect the pharmacokinetic properties of said compounds of the present invention. Those compounds having favorable pharmacokinetic properties would be apparent to the pharmaceutical chemist, i.e., those ~~which~~ that are non-toxic and ~~which~~ that possess such pharmacokinetic properties to provide sufficient palatability, absorption, distribution, metabolism and excretion. Other factors, more practical in nature, ~~which~~ that are also important in the selection, are cost of raw materials, ease of crystallization, yield, stability, hygroscopicity, and flowability of the resulting bulk drug. In addition, acceptable salts of carboxylates include sodium, potassium, calcium and magnesium. Examples of suitable cationic salts include hydrobromic, hydroiodic, hydrochloric, perchloric, sulfuric, maleic, fumaric, malic, tartatic, citric, benzoic, mandelic, methanesulfonic, hydroethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic and saccharic. Examples of suitable esters include such esters where one or more carboxyl substituents is replaced with p-methoxybenzyloxycarbonyl, 2,4,6-trimethylbenzyloxycarbonyl, 9-anthryloxycarbonyl, $\text{CH}_3\text{SCH}_2\text{COO}-$, tetrahydrofur-2-yloxycarbonyl, tetrahydropyran-2-yloxycarbonyl, fur-2-uloxycarbonyl, benzoylmethoxycarbonyl, p-nitrobenzyloxycarbonyl, 4-pyridylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2,2,2-tribromoethoxycarbonyl, t-butyloxycarbonyl, t-amylloxycarbonyl, diphenylmethoxycarbonyl, triphenylmethoxycarbonyl, adamantyloxycarbonyl, 2-benzyloxyphenyloxycarbonyl, 4-methylthiophenyloxycarbonyl, or tetrahydropyran-2-yloxycarbonyl.

The provisos are based on a failure to find activity in at least one compound meeting the specifications of each proviso.


Preferred compounds of Formula I are compounds selected from the group consisting of:




Additional preferred compounds of Formula I are compounds selected from the group consisting of:



10 Additional preferred compounds of Formula I are compounds selected from the group consisting of:





Still further preferred compounds are made according to the synthetic methods outlined in Schemes 1–4 where Y is S and selected from the group consisting of:

EX	COMPOUND
26	(2,3-Dimethyl-6H-thieno[2,3-b]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone;
27	(2-Chloro-3-methyl-6H-thieno[2,3-b]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone;
28	(3-Chloro-2-methyl-6H-thieno[2,3-b]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone;

- 29 (2-Bromo-6*H*-thieno[2,3-*b*]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone;
- 30 (3-Bromo-6*H*-thieno[2,3-*b*]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone;
- 31 (4-Methyl-piperazin-1-yl)-(2-phenyl-6*H*-thieno[2,3-*b*]pyrrol-5-yl)-methanone;
- 32 [2-(4-Chloro-phenyl)-6*H*-thieno[2,3-*b*]pyrrol-5-yl]-(4-methyl-piperazin-1-yl)-methanone;
- 33 (3-Bromo-4*H*-thieno[3,2-*b*]pyrrol-5-yl)-(3,4-dimethyl-piperazin-1-yl)-methanone;
- 34 (3,4-Dimethyl-piperazin-1-yl)-(3-methyl-4*H*-thieno[3,2-*b*]pyrrol-5-yl)-methanone;
- 35 (2-Bromo-3-methyl-4*H*-thieno[3,2-*b*]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone;
- 36 (3-Bromo-2-chloro-4*H*-thieno[3,2-*b*]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone;
- 37 (2,3-Dichloro-4*H*-thieno[3,2-*b*]pyrrol-5-yl)-(3-methyl-piperazin-1-yl)-methanone;
- 38 (4-Methyl-piperazin-1-yl)-(2-phenyl-4*H*-thieno[3,2-*b*]pyrrol-5-yl)-methanone; and
- 39 (4-Methyl-piperazin-1-yl)-[2-(4-trifluoromethyl-phenyl)-4*H*-thieno[3,2-*b*]pyrrol-5-yl]-methanone.

The following terms are defined below, and by their usage throughout the disclosure.

5 "Alkyl" includes straight chain and branched hydrocarbons with at least one hydrogen removed to form a radical group. Alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, 1-methylpropyl, pentyl, isopentyl, sec-pentyl, hexyl, heptyl, octyl, and so on. Alkyl does not include cycloalkyl.

"Alkenyl" includes straight chain and branched hydrocarbon radicals as above with at least one carbon-carbon double bond (sp^2). Alkenyls include
10 ethenyl (or vinyl), prop-1-enyl, prop-2-enyl (or allyl), isopropenyl (or 1-

methylvinyl), but-1-enyl, but-2-enyl, butadienyls, pentenyls, hexa-2,4-dienyl, and so on. Alkenyl does not include cycloalkenyl.

5 "Alkoxy" includes a straight chain or branched alkyl group with a terminal oxygen linking the alkyl group to the rest of the molecule. Alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy and so on. "Aminoalkyl", "thioalkyl", and "sulfonylalkyl" are analogous to alkoxy, replacing the terminal oxygen atom of alkoxy with, respectively, NH (or NR), S, and SO₂.

"Cycloalkyl" includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and so on.


10 "Halo" includes fluoro, chloro, bromo, and iodo, and preferably fluoro or chloro.

"Patient" or "subject" includes mammals such as humans and animals (dogs, cats, horses, rats, rabbits, mice, non-human primates) in need of observation, experiment, treatment or prevention in connection with the
15 relevant disease or condition. Preferably, the patient is a human.

"Composition" includes a product comprising the specified ingredients in the specified amounts as well as any product that results directly or indirectly from combinations of the specified ingredients in the specified amounts.

The compounds as described above may be made according to
20 processes within the skill of the art and/or that are described in the schemes and examples that follow. To obtain the various compounds herein, starting materials may be employed that carry the ultimately desired substituents though the reaction scheme with or without protection as appropriate. Alternatively, it may be necessary to employ, in the place of the ultimately
25 desired substituent, a suitable group that may be carried through the reaction scheme and replaced as appropriate with the desired substituent.


SCHEME 1



- 5 Referring to Scheme 1, there are disclosed the following notes and additions. Various R^1 may be obtained from E1 or C1 by treatment with a base and an appropriate alkylating agent. Where R^2 is halo, it may be obtained by treatment of E1 and C1 with an appropriate halogenating agent. Where R^2 is alkyl, it may be obtained by replacing the aldehyde of A1 with a ketone. P
- 10 may be an alkyl, aryl or benzyl. Suitable bases include NaOEt, LDA, NaH,

DBU, etc. The conversion of B1 to C1 is thermolytic with typical temperatures ranging from 80 to 200 °C. Suitable solvents for the conversion of B1 to C1 are xylene, cumene, diphenylether, etc. Acidic or basic hydrolysis will provide deprotection. In the case where P is benzyl, hydrogenolysis is also useful for
5 deprotection. Typical coupling reagents for the conversion of D1 to E1 include EDCI, HBTU, etc. Typical chlorination agents for the conversion of D1 to E1 include oxalyl chloride and thionyl chloride. X is a halogenating agent such as Cl₂, N-bromosuccinimide, TAS-F, Br₂, N-chlorosuccinimide, etc.

SCHEME 2




- 5 Referring to Scheme 2, there are disclosed the following notes and additions. Various R^1 may be obtained from E2 or C2 by treatment with a base and an appropriate alkylating agent. Where R^2 is halo, it may be obtained by treatment of E2 and C2 with an appropriate halogenating agent. Where R^2 is alkyl, it may be obtained by replacing the aldehyde of A2 with a ketone. P
- 10 may be an alkyl, aryl or benzyl. Suitable bases include NaOEt, LDA, NaH,

DBU, etc. The conversion of B2 to C2 is thermolytic with typical temperatures ranging from 80 to 200 °C. Suitable solvents for the conversion of B2 to C2 are xylene, cumene, diphenylether, etc. Acidic or basic hydrolysis will provide deprotection. In the case where P is benzyl, hydrogenolysis is also useful for deprotection. Typical coupling reagents for the conversion of D2 to E2 include EDCI, HBTU, etc. Typical chlorination agents for the conversion of D2 to E2 include oxalyl chloride and thionyl chloride. X is a halogenating agent such as Cl₂, N-bromosuccinimide, TAS-F, Br₂, N-chlorosuccinimide, etc.

10


SCHEME 3



15

Referring to Scheme 3, there are disclosed the following notes and additions. X is a halogenating agent such as Cl₂, N-bromosuccinimide, TAS-F, Br₂, N-chlorosuccinimide, etc.

SCHEME 4



20

Referring to Scheme 4, there are disclosed the following notes and additions. Typical bases include n-BuLi, LDA, t-BuLi, KHMDS.

The expression of the H₄ receptor in immune cells, including some leukocytes and mast cells, establishes it as an important target for therapeutic intervention in a range of immunological and inflammatory disorders (such as

25

allergic, chronic, or acute inflammation). Specifically H₄ receptor ligands are expected to be useful for the treatment or prevention of various mammalian disease states.

Thus, according to the invention, the disclosed compounds, where
5 antagonists of the H₄ receptor, and compositions are useful for the amelioration of symptoms associated with, the treatment of, and the prevention of, the following conditions and diseases: inflammatory disorders, asthma, psoriasis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, inflammatory
10 bowel disease, multiple sclerosis, allergic disorders, allergic rhinitis, dermatological disorders, autoimmune disease, lymphatic disorders, atherosclerosis, and immunodeficiency disorders. The disclosed compounds may also be useful as adjuvants in chemotherapy or in the treatment of itchy skin.

Aspects of the invention include (a) a pharmaceutical composition
15 comprising a compound of formula (I), or one or more preferred compounds as described herein, and a pharmaceutically acceptable carrier; (b) a packaged drug comprising (1) a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier, and (2) instructions for the administration of said composition for the treatment or prevention of an H₄-
20 mediated disease or condition.

The invention also provides a method for treating an H₄-mediated condition in a patient, said method comprising administering to the patient a pharmaceutically effective amount of a composition comprising a compound of formula (I) and other disclosed or preferred compounds. For example, the
25 invention features a method for treating an H₄ mediated condition in a patient, said method comprising administering to the patient a pharmaceutically effective H₄-antagonizing amount of a composition comprising a compound of formula (I).

The effect of an antagonist may also be produced by an inverse agonist.
30 Inverse agonism describes the property of a compound to actively turn off a receptor that displays constitutive activity. Constitutive activity can be identified in cells that have been forced to over-express the human H₄ receptor. Constitutive activity can be measured by examining cAMP levels or by

measuring a reporter gene sensitive to cAMP levels after a treatment with a cAMP-stimulating agent such as forskolin. Cells that over-express H₄ receptors will display lower cAMP levels after forskolin treatment than non-expressing cells. Compounds that behave as H₄ agonists will dose-dependently lower forskolin-stimulated cAMP levels in H₄-expressing cells. Compounds that behave as inverse H₄ agonists will dose-dependently stimulate cAMP levels in H₄-expressing cells. Compounds that behave as H₄ antagonists will block either H₄ agonist-induced inhibition of cAMP or inverse H₄ agonist-induced increases in cAMP.

Further embodiments of the invention include disclosed compounds that are inhibitors of a mammalian histamine H₄ receptor function, inhibitors of inflammation or inflammatory responses *in vivo* or *in vitro*, modulators of the expression of a mammalian histamine H₄ receptor protein, inhibitors of polymorphonuclear leukocyte activation *in vivo* or *in vitro*, or combinations of the above, and corresponding methods of treatment, prophylaxis, and diagnosis comprising the use of a disclosed compound.

Those skilled in the art will be able to determine, according to known methods, the appropriate dosage for a patient, taking into account factors such as age, weight, general health, the type of symptoms requiring treatment, and the presence of other medications. In general, an effective amount will be between 0.01 and 1000 mg/kg per day, preferably between 0.5 and 300 mg/kg body weight, and daily dosages will be between 10 and 5000 mg for an adult subject of normal weight. Capsules, tablets or other formulations (such as liquids and film-coated tablets) may be of between 0.5 and 200 mg, such as 1, 3, 5, 10, 15, 25, 35, 50 mg, 60 mg, and 100 mg and can be administered according to the disclosed methods.

Dosage unit forms include tablets, capsules, pills, powders, granules, aqueous and nonaqueous oral solutions and suspensions, and parenteral solutions packaged in containers adapted for subdivision into individual doses. Dosage unit forms can also be adapted for various methods of administration, including controlled release formulations, such as subcutaneous implants. Administration methods include oral, rectal, parenteral (intravenous, intramuscular, subcutaneous), intracisternal, intravaginal, intraperitoneal,

intravesical, local (drops, powders, ointments, gels or cream), and by inhalation (a buccal or nasal spray).

Parenteral formulations include pharmaceutically acceptable aqueous or nonaqueous solutions, dispersion, suspensions, emulsions, and sterile powders for the preparation thereof. Examples of carriers include water, ethanol, polyols (propylene glycol, polyethylene glycol), vegetable oils, and injectable organic esters such as ethyl oleate. Fluidity can be maintained by the use of a coating such as lecithin, a surfactant, or maintaining appropriate particle size. Carriers for solid dosage forms include (a) fillers or extenders, (b) binders, (c) humectants, (d) disintegrating agents, (e) solution retarders, (f) absorption accelerators, (g) adsorbants, (h) lubricants, (i) buffering agents, and (j) propellants.

Compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents; antimicrobial agents such as parabens, chlorobutanol, phenol, and sorbic acid; isotonic agents such as a sugar or sodium chloride; absorption-prolonging agents such as aluminum monostearate and gelatin; and absorption-enhancing agents.

EXAMPLES

20

GENERAL SYNTHETIC PROCEDURES

Procedure A: Annulation of Aldehyde with Ethyl Azidoacetate

A solution of aldehyde A1, A2 or A3 (1 equiv) and ethyl azidoacetate (4 equiv) was added dropwise to a solution of NaOEt (4 equiv) in EtOH (0.15 M) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h and at room temperature for an additional 1 h. The reaction mixture was then poured into satd aq NH₄Cl and extracted with ether. The combined organics were dried (Na₂SO₄) and concentrated *in vacuo*. The residue was purified by silica gel column chromatography to provide the desired acrylate.

30

A solution of the resultant acrylate in xylene (0.2 M) was heated at 145 °C for 10–60 min and then allowed to cool to room temperature. The xylene solution

was either cooled further to induce product crystallization or directly subjected to silica gel column chromatography to obtain the desired annulation product.

Procedure B: Ester Hydrolysis

- 5 A solution (0.2 M) of the ethyl ester (1 equiv, from Procedure A) and LiOH (5 equiv) in THF/MeOH/H₂O (3:1:1) was heated at 65 °C overnight, cooled to room temperature, acidified with 2 N HCl, and extracted with EtOAc. The organic layer was separated, dried over Na₂SO₄, and concentrated to give the desired crude acid, which was taken to the next step without further
10 purification.

Procedure C: Amide Formation Using 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide Hydrochloride (EDCI)

- A mixture of acid (1 equiv, from Procedure B), amine (1.5 equiv) and EDCI (2.0
15 equiv) in CH₂Cl₂ (0.2 M) was stirred at room temperature overnight and then partitioned between CH₂Cl₂ and satd aq NaHCO₃. The organic layer was separated, washed with H₂O, dried over Na₂SO₄, and concentrated. The crude product was further purified by silica gel column chromatography.

20 Procedure D: Amide Formation via Acyl Chloride Intermediate

- A mixture of acid (1 equiv, from Procedure B) in CH₂Cl₂ (0.5 M) was treated at 0 °C with oxalyl chloride (1.2 equiv) followed by 1–2 drops of DMF. The reaction mixture was stirred at 0 °C for 30 min then slowly warmed to room temperature and stirred for an additional 1 h. All volatiles were removed to
25 provide the crude acyl chloride.
- The resultant acyl chloride was treated with amine (5.0 equiv) in CH₂Cl₂ (0.2 M) and allowed to stir at room temperature for 3 h. The reaction mixture was partitioned between CH₂Cl₂ and satd aq NaHCO₃. The organic layer was separated, washed with H₂O, dried over Na₂SO₄, and concentrated. The crude
30 product was further purified with silica gel column chromatography.

GENERAL ANALYTICAL PROCEDURES

NMR spectra were obtained on either a Bruker model DPX400 (400 MHz) or DPX500 (500 MHz) spectrometer. The format of the ^1H NMR data below is: chemical shift in ppm down field of the tetramethylsilane reference (multiplicity, coupling constant J in Hz, integration).

5

Mass spectra were obtained on a Hewlett Packard (Agilent) series 1100 MSD using electrospray ionization (ESI) in either positive or negative mode as indicated. The "mass calculated" for a molecular formula is the monoisotopic mass of the compound.


10

Silica Gel Column Chromatography:

Normal-phase column chromatography was accomplished using an ISCO Foxy 200 system employing one of the following commercially available prepacked columns: ISCO Redisep (SiO_2 , 10 g, 12 g, 35 g, 40 g, or 120 g).

15

EXAMPLE 1



(4-Methyl-piperazin-1-yl)-(6H-thieno[2,3-b]pyrrol-5-yl)-methanone.

20

A. 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid ethyl ester. Thiophene-3-carbaldehyde (2.24 g, 20 mmol) was annulated according to Procedure A to provide the title compound (1.2 g, 31%) as a white solid. TLC (silica, 20% EtOAc/hexanes): R_f = 0.50. ^1H NMR (CDCl_3 , 400 MHz): 10.30 (br s, 1H), 7.10 (d, J = 1.9 Hz, 1H), 6.96 (d, J = 5.4 Hz, 1H), 6.87 (d, J = 5.4 Hz, 1H), 4.39 (q, J = 7.1 Hz, 2H), 1.38 (t, J = 7.1 Hz, 3H).

25

B. 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid. 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid ethyl ester (835 mg, 4.3 mmol) was hydrolyzed according to Procedure B to provide the crude acid as a pale-yellow solid. ^1H NMR (CD_3OD , 400 MHz): 7.02 (s, 1H), 6.96 (s, 1H), 6.95 (s, 1H).


30

C. (4-Methyl-piperazin-1-yl)-(6H-thieno[2,3-b]pyrrol-5-yl)-methanone. 6H-

Thieno[2,3-b]pyrrole-5-carboxylic acid (60 mg, 0.35 mmol) was coupled with N-methylpiperazine according to Procedure C to provide the title compound (44 mg, 50%) as a light yellow solid. TLC (silica, 10% MeOH/CH₂Cl₂): R_f = 0.4.

- 5 MS (electrospray): exact mass calculated for C₁₂H₁₅N₃OS, 249.09; *m/z* found, 250.1 [M+H]⁺. ¹H NMR (CD₃OD, 400 MHz, TFA salt): 6.97 (s, 1H), 6.96 (s, 1H), 6.85 (s, 1H), 4.20-3.10 (m, 8H), 2.96 (s, 3H).

EXAMPLE 2



10

(Hexahydro-pyrrolo[1,2-a]pyrazin-2-yl)-(6H-thieno[2,3-b]pyrrol-5-yl)-methanone.


6H-Thieno[2,3-b]pyrrole-5-carboxylic acid (60 mg, 0.35 mmol) was coupled with octahydro-pyrrolo[1,2-a]pyrazine according to Procedure C to provide the

15 title compound (34 mg, 35%) as a light yellow solid. TLC (silica, 10% MeOH/CH₂Cl₂): R_f = 0.4. MS (electrospray): exact mass calculated for C₁₄H₁₇N₃OS, 275.11; *m/z* found, 276.2 [M+H]⁺. ¹H NMR (CDCl₃, 400 MHz):

11.1 (br s, 1H), 6.96 (d, *J* = 5.4 Hz, 1H), 6.87 (d, *J* = 5.4 Hz, 1H), 6.71 (d, *J* = 1.9 Hz, 1H), 4.84 (d, *J* = 12.2 Hz, 1H), 4.70 (d, *J* = 12.2 Hz, 1H), 3.30-2.90 (m,

20 4H), 2.30-1.40 (m, 7H).

EXAMPLE 3



(2-Chloro-6H-thieno[2,3-b]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone.

25


A. 2-Chloro-6H-thieno[2,3-b]pyrrole-5-carboxylic acid ethyl ester. A solution of 6H-thieno[2,3-b]pyrrole-5-carboxylic acid ethyl ester (580 mg, 3.0 mmol) in

acetic acid (6 mL) and CHCl_3 (6 mL) was treated with three portions of *N*-chlorosuccinimide (total 415 mg, 3.15 mmol) at 0 °C over 2 h. The reaction mixture was slowly warmed to room temperature and stirred overnight. The CHCl_3 was then removed, and the residue was basified with 4 N NaOH and
 5 extracted with EtOAc. The combined organics were washed with satd aq NaHCO_3 , dried over Na_2SO_4 , and concentrated. Column chromatography (SiO_2 , 5–10% EtOAc/hexanes) gave 600 mg (88%) of a white solid. TLC (silica, 20% EtOAc/hexanes): R_f = 0.5. ^1H NMR (CDCl_3 , 400 MHz): 10.5 (br s, 1H), 6.97 (d, J = 2.0 Hz, 1H), 6.85 (s, 1H), 4.39 (q, J = 7.2 Hz, 2H), 1.35 (t, J =
 10 7.2 Hz, 3H).

B. (2-Chloro-6*H*-thieno[2,3-*b*]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone.
 2-Chloro-6*H*-thieno[2,3-*b*]pyrrole-5-carboxylic acid ethyl ester (102 mg, 0.45 mmol) was hydrolyzed (Procedure B) and coupled with *N*-methylpiperazine (procedure D) to provide the title compound (102 mg, 80% for two steps) as an
 15 off-white solid. TLC (silica, 10% MeOH/ CH_2Cl_2): R_f = 0.4. MS (electrospray): exact mass calculated for $\text{C}_{12}\text{H}_{14}\text{ClN}_3\text{OS}$, 283.05; m/z found, 284.1 $[\text{M}+\text{H}]^+$. ^1H NMR (CDCl_3 , 400 MHz): 10.5 (br s, 1H), 6.87 (s, 1H), 6.61 (d, J = 1.8 Hz, 1H), 3.92 (t, J = 5.1 Hz, 4H), 2.50 (t, J = 5.1 Hz, 4H), 2.35 (s, 3H).

20

EXAMPLE 4




(2-Chloro-6*H*-thieno[2,3-*b*]pyrrol-5-yl)-(hexahydro-pyrrolo[1,2-*a*]pyrazin-2-yl)-methanone.

25 2-Chloro-6*H*-thieno[2,3-*b*]pyrrole-5-carboxylic acid ethyl ester (102 mg, 0.45 mmol) was hydrolyzed (Procedure B) and then coupled with octahydro-pyrrolo[1,2-*a*]pyrazine (Procedure D) to provide the title compound (108 mg, 78% for two steps) as an off-white solid. TLC (silica, 10% MeOH/ CH_2Cl_2): R_f = 0.35. MS (electrospray): exact mass calculated for $\text{C}_{14}\text{H}_{16}\text{ClN}_3\text{OS}$, 309.07; m/z
 30 found, 310.1 $[\text{M}+\text{H}]^+$. ^1H NMR (CDCl_3 , 400 MHz): 11.1 (br s, 1H), 6.86 (s, 1H),

6.62 (s, 1H), 4.79 (d, $J = 11.8$ Hz, 1H), 4.67 (d, $J = 11.8$ Hz, 1H), 3.30-2.90 (m, 4H), 2.30-1.40 (m, 7H).

EXAMPLE 5




5

(2-Chloro-6H-thieno[2,3-b]pyrrol-5-yl)-piperazin-1-yl-methanone.

2-Chloro-6H-thieno[2,3-b]pyrrole-5-carboxylic acid ethyl ester (102 mg, 0.45 mmol) was hydrolyzed (Procedure B) and then coupled with piperazine (Procedure D) to provide the title compound (42 mg, 35% for two steps) as an off-white solid. TLC (silica, 10% MeOH/CH₂Cl₂): $R_f = 0.15$. MS (electrospray): exact mass calculated for C₁₁H₁₂ClN₃OS, 269.04; m/z found, 270.1 [M+H]⁺. ¹H NMR (CDCl₃, 400 MHz): 10.5 (br s, 1H), 6.87 (s, 1H), 6.61 (s, 1H), 3.87 (t, $J = 4.8$ Hz, 4H), 2.96 (t, $J = 5.2$ Hz, 4H).

15

EXAMPLE 6



(4H-Furo[3,2-b]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone.


20 A. 4H-Furo[3,2-b]pyrrole-5-carboxylic acid ethyl ester. Furan-2-carbaldehyde (1.92 g, 20 mmol) was annulated according to procedure A to provide the title compound (1.97 g, 55%) as a white solid. TLC (silica, 20% EtOAc/hexanes): $R_f = 0.50$. ¹H NMR (CDCl₃, 400 MHz): 8.95 (br s, 1H), 7.51 (d, $J = 2.2$ Hz, 1H), 6.81-6.80 (m, 1H), 6.46-6.45 (m, 1H), 4.35 (q, $J = 7.1$ Hz, 2H), 1.38 (t, $J = 7.1$ Hz, 3H).

25

B. (4H-Furo[3,2-b]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone. 4H-Furo[3,2-b]pyrrole-5-carboxylic acid ethyl ester (200 mg, 1.12 mmol) was hydrolyzed (Procedure B) and coupled with N-methylpiperazine (Procedure D)

to provide the title compound (185 mg, 71% for two steps) as an off-white solid. TLC (silica, 10% MeOH/CH₂Cl₂): R_f = 0.4. MS (electrospray): exact mass calculated for C₁₂H₁₅N₃O₂, 233.12; *m/z* found, 234.2 [M+H]⁺. ¹H NMR (CDCl₃, 400 MHz): 10.3 (br s, 1H), 7.43 (d, *J* = 2.2 Hz, 1H), 6.43-6.42 (m, 2H), 3.90 (t, *J* = 5.0 Hz, 4H), 2.47 (t, *J* = 5.1 Hz, 4H), 2.32 (s, 3H).

EXAMPLE 7



(4-Methyl-piperazin-1-yl)-(4*H*-thieno[3,2-*b*]pyrrol-5-yl)-methanone.

10


A. 4*H*-Thieno[3,2-*b*]pyrrole-5-carboxylic acid ethyl ester. To a solution of thiophene-2-carbaldehyde (1.10 mL, 11.7 mmol) and ethyl azidoacetate (1.4 mL, 11.7 mmol) in EtOH (35 mL) cooled to 0 °C was added NaOEt (1.0 g, 14.7 mmol) in one portion. The mixture was allowed to reach room temperature over 14 h and was then poured into water (400 mL) and extracted with CH₂Cl₂ (3 X 50 mL). The combined organics were washed with water and brine, dried over Na₂SO₄, and concentrated. The residue was taken up in xylenes (10 mL), and the resulting solution was refluxed for 1 h. The solution was cooled and then loaded directly onto silica gel and purified (35 g SiO₂, 10–20%

EtOAc/hexanes) to reveal 0.12 g (5%) of a yellowish solid. ¹H NMR (400 MHz, CDCl₃): 9.06 (br s, 1H), 7.33 (d, *J* = 5.3 Hz, 1H), 7.15-7.14 (m, 1H), 6.96 (dd, *J* = 5.3, 0.8 Hz, 1H), 4.37 (q, *J* = 7.3 Hz, 2H), 1.39 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): 161.3, 140.9, 129.2, 126.9, 124.6, 110.9, 107.3, 60.4, 14.2.

B. (4-Methyl-piperazin-1-yl)-(4*H*-thieno[3,2-*b*]pyrrol-5-yl)-methanone. To a solution of 4*H*-thieno[3,2-*b*]pyrrole-5-carboxylic acid ethyl ester (98.5 mg, 0.50 mmol) in wet THF (3 mL) was added LiOH (129 mg, 3 mmol). This mixture was stirred at room temperature for 3 days. The reaction mixture was diluted with water (50 mL), and 1 M HCL was added to adjust the pH to about 3. This mixture was then extracted with EtOAc, and the combined organics were dried over Na₂SO₄. The solvent was removed to reveal 73.4 mg (87%) of the free

acid, which was used in the coupling event without further purification. The acid (73.4 mg, 0.44 mmol) was taken up in THF (3 mL), and CDI (87.1 mg, 0.54 mmol) was added in one portion. The reaction mixture was stirred for 1 h. To this mixture was then added 1-methylpiperazine (70 μ L), and the mixture stirred for an additional 6 h. The reaction mixture was diluted with EtOAc, washed with water, NaHCO₃ (aq) and then brine, and subsequently purified by column chromatography (10 g SiO₂, 1–8% MeOH (2 M NH₃)/CH₂Cl₂) to reveal 55.6 mg (51%) of the title compound. ¹H NMR (400 MHz, CDCl₃): 9.26 (br s, 1H), 7.26 (d, *J* = 5.3 Hz, 1H), 6.97 (dd, *J* = 5.3, 0.8 Hz, 1H), 6.75–6.74 (m, 1H), 4.07–3.88 (m, 4H), 2.68–2.48 (m, 4H), 2.43 (br s, 3H). MS (electrospray): exact mass calculated for C₁₂H₁₅N₃OS, 249.09; *m/z* found, 250.1 [M+H]⁺.


EXAMPLE 8



Piperazin-1-yl-(4*H*-thieno[3,2-*b*]pyrrol-5-yl)-methanone.

4*H*-Thieno[3,2-*b*]pyrrole-5-carboxylic acid (50 mg, 0.30 mmol) was coupled with piperazine according to Procedure D to provide the title compound (25 mg, 35%) as an off-white solid. TLC (silica, 10% MeOH/CH₂Cl₂): *R_f* = 0.15. MS (electrospray): exact mass calculated for C₁₁H₁₃N₃OS, 235.08; *m/z* found, 236.1 [M+H]⁺. ¹H NMR (CD₃OD, 400 MHz): 7.33 (d, *J* = 5.3 Hz, 1H), 6.98 (dd, *J* = 5.2, 0.7 Hz, 1H), 6.89 (d, *J* = 0.6 Hz, 1H), 4.08 (t, *J* = 5.3 Hz, 4H), 3.50–3.20 (m, 4H).


EXAMPLE 9



(3-Methyl-piperazin-1-yl)-(4*H*-thieno[3,2-*b*]pyrrol-5-yl)-methanone.

- 4*H*-Thieno[3,2-*b*]pyrrole-5-carboxylic acid (50 mg, 0.30 mmol) was coupled with 2-methylpiperazine according to Procedure D to provide the title compound (58 mg, 78%) as an off-white solid. TLC (silica, 10% MeOH/CH₂Cl₂): *R_f* = 0.15. MS (electrospray): exact mass calculated for C₁₂H₁₅N₃OS, 249.09; *m/z* found, 250.1 [M+H]⁺. ¹H NMR (CD₃OD, 400 MHz): 7.33 (d, *J* = 5.3 Hz, 1H), 6.98 (d, *J* = 5.3 Hz, 1H), 6.88 (s, 1H), 4.62-4.56 (m, 2H), 3.50-3.20 (m, 5H), 1.36 (d, *J* = 6.6 Hz, 3H).

EXAMPLE 10




10

(2-Chloro-4*H*-thieno[3,2-*b*]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone.

- A. 2-Chloro-4*H*-thieno[3,2-*b*]pyrrole-5-carboxylic acid ethyl ester. 5-Chloro-thiophene-2-carbaldehyde (2.92 g, 20 mmol) was annulated according to Procedure A to provide the title compound (2.8 g, 61%) as a white solid. TLC (silica, 20% EtOAc/hexanes): *R_f* = 0.48. ¹H NMR (CDCl₃, 400 MHz): 9.10 (br s, 1H), 7.04 (dd, *J* = 1.9, 0.7 Hz, 1H), 6.89 (d, *J* = 0.7 Hz, 1H), 4.37 (q, *J* = 7.2 Hz, 2H), 1.39 (t, *J* = 7.2 Hz, 3H).

- B. (2-Chloro-4*H*-thieno[3,2-*b*]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone. 2-Chloro-4*H*-thieno[3,2-*b*]pyrrole-5-carboxylic acid ethyl ester (230 mg, 1.0 mmol) was hydrolyzed (Procedure B) and then coupled with *N*-methylpiperazine (Procedure C) to provide the title compound (128 mg, 45% for two steps) as an off-white solid. TLC (silica, 10% MeOH/CH₂Cl₂): *R_f* = 0.4. MS (electrospray): exact mass calculated for C₁₂H₁₄ClN₃OS, 283.05; *m/z* found, 284.1 [M+H]⁺. ¹H NMR (CDCl₃, 400 MHz): 10.1 (br s, 1H), 6.88 (s, 1H), 6.64 (d, *J* = 1.4 Hz, 1H), 3.91 (t, *J* = 4.4 Hz, 4H), 2.49 (t, *J* = 5.1 Hz, 4H), 2.35 (s, 3H).

EXAMPLE 11



(2-Chloro-4*H*-thieno[3,2-*b*]pyrrol-5-yl)-(hexahydro-pyrrolo[1,2-*a*]pyrazin-2-yl)-methanone.


5

2-Chloro-4*H*-thieno[3,2-*b*]pyrrole-5-carboxylic acid ethyl ester (230 mg, 1.0 mmol) was hydrolyzed (Procedure B) and then coupled with octahydro-pyrrolo[1,2-*a*]pyrazine (Procedure C) to provide the title compound (93 mg, 30% for two steps) as an off-white solid. TLC (silica, 10% MeOH/CH₂Cl₂): R_f = 0.4. MS (electrospray): exact mass calculated for C₁₄H₁₆ClN₃OS, 309.07; *m/z* found, 310.1 [M+H]⁺. ¹H NMR (CDCl₃, 400 MHz): 10.9 (br s, 1H), 6.86 (s, 1H), 6.64 (d, *J* = 1.4 Hz, 1H), 4.77 (d, *J* = 12.2 Hz, 1H), 4.65 (d, *J* = 12.7 Hz, 1H), 3.30-2.90 (m, 4H), 2.30-1.40 (m, 7H).

10

15

EXAMPLE 12




(3-Bromo-4*H*-thieno[3,2-*b*]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone.

- A. 3-Bromo-4*H*-thieno[3,2-*b*]pyrrole-5-carboxylic acid ethyl ester. 4-Bromo-thiophene-2-carbaldehyde (3.8 g, 20 mmol) was annulated according to Procedure A to provide the title compound (1.2 g, 22%) as a white solid. TLC (silica, 20% EtOAc/hexanes): R_f = 0.48. ¹H NMR (CDCl₃, 400 MHz): 9.58 (br s, 1H), 7.20 (s, 1H), 7.15 (d, *J* = 1.5 Hz, 1H), 4.41 (q, *J* = 7.2 Hz, 2H), 1.39 (t, *J* = 7.2 Hz, 3H).
- 20 B. (3-Bromo-4*H*-thieno[3,2-*b*]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone. 3-Bromo-4*H*-thieno[3,2-*b*]pyrrole-5-carboxylic acid ethyl ester (67 mg, 0.24 mmol) was hydrolyzed (Procedure B) and then coupled with *N*-

methylpiperazine (Procedure D) to provide the title compound (65 mg, 82% for two steps) as an off-white solid. TLC (silica, 10% MeOH/CH₂Cl₂): R_f = 0.4. MS (electrospray): exact mass calculated for C₁₂H₁₄BrN₃OS, 327.00; *m/z* found, 328.0 [M+H]⁺. ¹H NMR (CDCl₃, 400 MHz): 9.95 (br s, 1H), 7.11 (s, 1H), 6.73 (d, *J* = 1.8 Hz, 1H), 3.91 (t, *J* = 5.1 Hz, 4H), 2.49 (t, *J* = 5.1 Hz, 4H), 2.34 (s, 3H).

EXAMPLE 13



(4-Methyl-piperazin-1-yl)-(3-methyl-4*H*-thieno[3,2-*b*]pyrrol-5-yl)-methanone.

A. 4-methyl-thiophene-2-carbaldehyde. A solution of 3-methylthiophene (6.76 mL, 70 mmol) in ether (70 mL) was treated with *n*-butyllithium (2.5 M in hexanes, 28.6 mL, 71.4 mmol) at such a rate that a slight reflux was maintained. The reaction mixture was heated to reflux for 15 min and then DMF (7.0 mL, 91 mmol) in ether (30 mL) was added. After stirring for 4 h, the reaction was quenched with addition of satd aq NH₄Cl (200 mL). The organic layer was separated, washed with brine and then H₂O, dried over Na₂SO₄, and concentrated. Column chromatography (SiO₂, 5–10% EtOAc/hexanes) provided a mixture of 4-methyl-thiophene-2-carbaldehyde and 3-methyl-thiophene-2-carbaldehyde (4.4:1, 8.1 g, 92%) as a light yellow oil. TLC (silica, 10% EtOAc/hexanes): R_f = 0.55. For 4-methyl-thiophene-2-carbaldehyde: ¹H NMR (CDCl₃, 400 MHz): 9.95 (s, 1H), 7.58 (d, *J* = 1.2 Hz, 1H), 7.37-7.35 (m, 1H), 2.32 (s, 3H). For 3-methyl-thiophene-2-carbaldehyde: ¹H NMR (CDCl₃, 400 MHz): 10.02 (s, 1H), 7.64 (d, *J* = 4.6 Hz, 1H), 6.97 (d, *J* = 4.6 Hz, 1H), 2.58 (s, 3H).


B. 3-Methyl-4*H*-thieno[3,2-*b*]pyrrole-5-carboxylic acid ethyl ester. The mixture of 4-methyl-thiophene-2-carbaldehyde and 3-methyl-thiophene-2-carbaldehyde (2.84 g, 22.5 mmol) was annulated according to Procedure A to provide the title compound (2.5 g, 65%) as a white solid. TLC (silica, 20%

EtOAc/hexanes): R_f = 0.45. ^1H NMR (CDCl_3 , 400 MHz): 9.95 (br s, 1H), 7.12 (d, J = 1.9 Hz, 1H), 6.90 (d, J = 1.2 Hz, 1H), 4.39 (q, J = 7.2 Hz, 2H), 2.35 (s, 3H), 1.39 (t, J = 7.2 Hz, 3H).

C. (4-Methyl-piperazin-1-yl)-(3-methyl-4H-thieno[3,2-b]pyrrol-5-yl)-methanone.

- 5 3-Methyl-4H-thieno[3,2-b]pyrrole-5-carboxylic acid ethyl ester (200 mg, 0.96 mmol) was hydrolyzed (Procedure B) and then coupled with *N*-methylpiperazine (Procedure D) to provide the title compound (197 mg, 78% for two steps) as an off-white solid. TLC (silica, 10% MeOH/ CH_2Cl_2): R_f = 0.4. MS (electrospray): exact mass calculated for $\text{C}_{13}\text{H}_{17}\text{N}_3\text{OS}$, 263.11; m/z found, 10 264.1 $[\text{M}+\text{H}]^+$. ^1H NMR (CDCl_3 , 400 MHz): 11.10 (br s, 1H), 6.76 (d, J = 1.2 Hz, 1H), 6.69 (d, J = 2.0 Hz, 1H), 3.94-3.90 (m, 4H), 2.47 (t, J = 5.1 Hz, 4H), 2.33 (s, 3H), 2.25 (s, 3H).

EXAMPLE 14




15

(2-Methyl-4H-furo[3,2-b]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone.

- A. 2-Methyl-4H-furo[3,2-b]pyrrole-5-carboxylic acid ethyl ester. 5-Methyl-furan-2-carbaldehyde (2.2 g, 20 mmol) was annulated according to Procedure A to provide the title compound (2.89 g, 75%) as a white solid. TLC (silica, 10% EtOAc/hexanes): R_f = 0.4. ^1H NMR (CDCl_3 , 400 MHz): 9.50 (br s, 1H), 6.73 (s, 1H), 6.04 (s, 1H), 4.35 (q, J = 7.2 Hz, 2H), 2.37 (s, 3H), 1.35 (t, J = 7.2 Hz, 3H). 20
- B. (2-Methyl-4H-furo[3,2-b]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone. 2-Methyl-4H-furo[3,2-b]pyrrole-5-carboxylic acid ethyl ester (200 mg, 1.04 mmol) was hydrolyzed (Procedure B) and then coupled with *N*-methylpiperazine (Procedure D) to provide the title compound (208 mg, 81% for two steps) as a white solid. TLC (silica, 10% MeOH/ CH_2Cl_2): R_f = 0.35. MS (electrospray): exact mass calculated for $\text{C}_{13}\text{H}_{17}\text{N}_3\text{O}_2$, 247.13; m/z found, 248.2 $[\text{M}+\text{H}]^+$. ^1H NMR (CDCl_3 , 400 MHz): 9.85 (br s, 1H), 6.36 (s, 1H), 6.07 (s, 1H), 3.87 (t, J = 5.0 Hz, 4H), 2.47 (t, J = 5.2 Hz, 4H), 2.39 (s, 3H), 2.33 (s, 3H). 30

EXAMPLE 15



(2,3-Dimethyl-4*H*-furo[3,2-*b*]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone.

5

A. 2,3-Dimethyl-4*H*-furo[3,2-*b*]pyrrole-5-carboxylic acid ethyl ester. 4,5-

Dimethyl-furan-2-carbaldehyde (2.2 g, 18 mmol) was annulated according to Procedure A to provide the title compound (1.76 g, 48%) as an off-white solid.

TLC (silica, 10% EtOAc/hexanes): R_f = 0.35. ^1H NMR (CDCl_3 , 400 MHz): 8.95

10 (br s, 1H), 6.69 (d, J = 1.7 Hz, 1H), 4.32 (q, J = 7.2 Hz, 2H), 2.33 (s, 3H), 2.08 (s, 3H), 1.37 (t, J = 7.2 Hz, 3H).

B. (2,3-Dimethyl-4*H*-furo[3,2-*b*]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-

methanone. 2,3-Dimethyl-4*H*-furo[3,2-*b*]pyrrole-5-carboxylic acid ethyl ester


(200 mg, 0.97 mmol) was hydrolyzed (Procedure B) and then coupled with *N*-

15 methylpiperazine (Procedure D) to provide the title compound (190 mg, 75%

for two steps) as an off-white solid. TLC (silica, 10% MeOH/ CH_2Cl_2): R_f = 0.35.

MS (electrospray): exact mass calculated for $\text{C}_{14}\text{H}_{19}\text{N}_3\text{O}_2$, 261.15; m/z found, 261.8 $[\text{M}+\text{H}]^+$. ^1H NMR (CDCl_3 , 400 MHz): 9.95 (br s, 1H), 6.32 (d, J = 1.8 Hz, 1H), 3.88 (t, J = 5.0 Hz, 4H), 2.47 (t, J = 5.1 Hz, 4H), 2.33 (s, 3H), 2.31 (s, 3H),
20 2.06 (s, 3H).

EXAMPLE 16



(2,3-Dimethyl-4*H*-thieno[3,2-*b*]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone.

25

A. 2,3-Dimethyl-4*H*-thieno[3,2-*b*]pyrrole-5-carboxylic acid ethyl ester. 4,5-

Dimethyl-thiophene-2-carbaldehyde (2.0 g, 14 mmol) was annulated according

to Procedure A to provide the title compound (160 mg, 5%) as a white solid.

TLC (silica, 10% EtOAc/hexanes): R_f = 0.40. ^1H NMR (CDCl_3 , 400 MHz): 9.50 (br s, 1H), 7.05 (d, J = 1.9 Hz, 1H), 4.36 (q, J = 7.2 Hz, 2H), 2.41 (s, 3H), 2.22 (s, 3H), 1.38 (t, J = 7.2 Hz, 3H).

- 5 B. (2,3-Dimethyl-4*H*-thieno[3,2-*b*]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone. 2,3-Dimethyl-4*H*-thieno[3,2-*b*]pyrrole-5-carboxylic acid ethyl ester (68 mg, 0.30 mmol) was hydrolyzed (Procedure B) and then coupled with *N*-methylpiperazine (Procedure D) to provide the title compound (67 mg, 80% for two steps) as an off-white solid. TLC (silica, 10% MeOH/ CH_2Cl_2): R_f = 0.35.

- 10 MS (electrospray): exact mass calculated for $\text{C}_{14}\text{H}_{19}\text{N}_3\text{OS}$, 277.12; m/z found, 278.1 $[\text{M}+\text{H}]^+$. ^1H NMR (CDCl_3 , 400 MHz): 10.95 (br s, 1H), 6.63 (d, J = 1.9 Hz, 1H), 3.92 (t, J = 4.5 Hz, 4H), 2.46 (t, J = 5.0 Hz, 4H), 2.36 (s, 3H), 2.33 (s, 3H), 2.13 (s, 3H).

15

EXAMPLES 17–25

The following compounds were made according to the synthetic methods outlined in Schemes 1–4:

EX

COMPOUND

- 17 (2,3-Dichloro-6*H*-thieno[2,3-*b*]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone;
- 18 (2-Methyl-4*H*-furo[3,2-*b*]pyrrol-5-yl)-piperazin-1-yl-methanone;
- 19 (3-Bromo-4*H*-thieno[3,2-*b*]pyrrol-5-yl)-piperazin-1-yl-methanone;
- 20 (3-Bromo-4*H*-thieno[3,2-*b*]pyrrol-5-yl)-(3-methyl-piperazin-1-yl)-methanone;
- 21 (3-Methyl-4*H*-thieno[3,2-*b*]pyrrol-5-yl)-piperazin-1-yl-methanone;
- 22 (3-Methyl-piperazin-1-yl)-(3-methyl-4*H*-thieno[3,2-*b*]pyrrol-5-yl)-methanone;
- 23 (2-Chloro-3-methyl-4*H*-thieno[3,2-*b*]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone;
- 24 (2-Chloro-3-methyl-4*H*-thieno[3,2-*b*]pyrrol-5-yl)-piperazin-1-yl-methanone; and

25 (2,3-Dichloro-4*H*-thieno[3,2-*b*]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone.

Biological Examples

Binding Assay on Recombinant Human Histamine H₄ Receptor

- 5 SK-N-MC cells or COS7 cells were transiently transfected with pH4R and grown in 150 cm² tissue culture dishes. Cells were washed with saline solution, scraped with a cell scraper and collected by centrifugation (1000 rpm, 5 min). Cell membranes were prepared by homogenization of the cell pellet in 20 mM Tris-HCl with a polytron tissue homogenizer for 10 s at high speed.
- 10 Homogenate was centrifuged at 1000 rpm for 5 min at 4 °C. The supernatant was then collected and centrifuged at 20,000 x g for 25 min at 4 °C. The final pellet was resuspended in 50 mM Tris-HCl. Cell membranes were incubated with ³H-histamine (5-70 nM) in the presence or absence of excess histamine (10000 nM). Incubation occurred at room temperature for 45 min. Membranes
- 15 were harvested by rapid filtration over Whatman GF/C filters and washed 4 times with ice-cold 50 mM Tris HCl. Filters were then dried, mixed with scintillant and counted for radioactivity. SK-N-MC or COS7 cells expressing human histamine H₄ receptor were used to measure the affinity of binding of other compounds and their ability to displace ³H-ligand binding by incubating
- 20 the above-described reaction in the presence of various concentrations of inhibitor or compound to be tested. For competition binding studies using ³H-histamine, K_i values were calculated, based on an experimentally determined K_D value of 5 nM and a ligand concentration of 5 nM, according to Y.-C. Cheng and W.H. Prusoff (*Biochem. Pharmacol.* 1973, 22(23):3099–
- 25 3108): $K_i = (IC_{50}) / (1 + ([L]/(K_D)))$.

BINDING ASSAY RESULTS

<u>EX</u>	<u>K_i (nM)</u>	<u>EX</u>	<u>K_i (nM)</u>
1	85	13	21
2	461	14	343

3	25	15	140
4	176	16	5
5	56	17	10
6	840	18	770
7	125	19	410
8	343	20	980
9	733	21	80
10	40	22	161
11	715	23	3
12	56	24	30
		25	5.5

Mast Cell Chemotaxis Assay

- Mast cell accumulation in mucosal epithelia is a well-known characteristic of allergic rhinitis and asthma. Transwells (Costar, Cambridge, MA) of a pore size
- 5 8 μm were coated with 100 μL of 100 ng/mL human fibronectin (Sigma) for 2 h at room temperature. After removal of the fibronectin, 600 μL of RPMI with 5% BSA, in the presence of 10 μM histamine, was added to the bottom chamber. To test the various histamine receptor (HR) antagonists, 10 μM and/or 1 μM solutions of the test compounds were added to the top and bottom chambers.
- 10 Mast cells ($2 \times 10^5/\text{well}$) were added to the top chamber. The plates were incubated for 3 h at 37 °C. Transwells were removed and the cells in the bottom chamber were counted for sixty seconds using a flow cytometer.

10 μ M Histamine	HR Antagonist (μ M) :				Binding Assay
	10		1		
EX	% Inh	Stdev	% Inh	Stdev	K _i (nM)
3	106	4	103	0	25
4	<5	--	<5	--	176
10			92	3	40

13			60	20	21
20	<5	--	<5	--	980

Cell-type Distribution of H₄ Expression

RNA was prepared from the different cells using an RNeasy kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. RNA samples (5 µg) were run on an RNA gel and then transferred overnight to a nylon blot (Hybond, Amersham Pharmacia Biotech, Piscataway, NJ). The blot was pre-hybridized with ExpressHyb solution (CLONTECH) for 30 min at 68 °C. The H₄ receptor DNA was labeled using the Rediprime II kit (Amersham Pharmacia Biotech). The blot was hybridized for 2 h at 68 °C, followed by one wash step (23 SSC and 0.05% SDS) of 40 min at room temperature, and a second wash step (0.13 SSC and 0.1% SDS) of 40 min at 50 °C. The blot was exposed to X-ray film at -70 °C with two intensifying screens overnight.

Results

The Northern Blot results indicate that the H₄ receptor is expressed on bone marrow-derived mast cells (BMMC), peritoneal mast cells, and eosinophils. These positive results are consistent with the published literature (e.g. Oda et al., Nguyen et al., and Morse et al. in the Background section). However, the negative results of the Northern Blot experiment, such as the finding of apparently no measurable levels of H₄ receptor expressed by neutrophils, differ somewhat from the above literature findings. This may be explained by the different methodologies used. Accumulation of mast cells and eosinophils in affected tissues is one of the principal characteristics of allergic rhinitis and asthma. Since H₄ receptor expression is limited to these cell types; H₄ receptor signalling is likely to mediate the infiltration of mast cells and eosinophils in response to histamine. Additional investigation may also clarify these issues. The following table reports the Cell-type Distribution of H₄ Expression by Northern Blot.

Species	Cell Type	H ₄
---------	-----------	----------------

Human	Eosinophils	+
	Immature Dendritic Cells	-
	Mature Dendritic Cells	-
	CD14 ⁺ Monocytes	-
	CD4 ⁺ T Cells	-
	CD8 ⁺ T Cells	-
	B Cells	-
	Neutrophils	-
<hr/>		
Mouse/(Rat)	Eosinophils	+
	Peritoneal Mast Cells (Rat)	+
	BMMC	+
	BM Derived Macrophages	-
	Peritoneal Macrophages	-
	CD4 ⁺ T Cells	-
	B Cells	-
<hr/>		

The Inhibition of Eosinophil Shape Change by Histamine H₄ Receptor Antagonists

- Eosinophil accumulation in sites of allergic reaction is a well-known
- 5 characteristic of allergic rhinitis and asthma. This example demonstrates that histamine H₄ receptor antagonists can block the shape change response in human eosinophils in response to histamine. Shape change is a cellular characteristic that precedes eosinophil chemotaxis.

Methods

- 10 Human granulocytes were isolated from human blood by a Ficoll gradient. The red blood cells were lysed with 5-10X Qiagen lysis buffer at room temperature for 5–7 min. Granulocytes were harvested and washed once with FACS buffer. The cells were resuspended at a density of 2×10^6 cells/mL in reaction buffer. To test inhibition by specific histamine receptor antagonists, 90 μ L of the cell
- 15 suspension ($\sim 2 \times 10^5$ cells) was incubated with 10 μ M of one of the various test compound solutions. After 30 min, 11 μ L of one of the various concentrations of histamine was added. Ten minutes later the cells were transferred to ice

and fixed with 250 μ L of ice-cold fixative buffer (2% formaldehyde) for 1 min. The shape change was quantitated using a gated autofluorescence forward scatter assay (GAFS) (Byran et al., *Am. J. Crit. Care Med.* 2002, 165:1602–1609).

5 Results - Histamine Mediates Eosinophil Shape Change Through H₄ Receptor

The change in shape of eosinophils is due to cytoskeletal changes that preceed chemotaxis and thus is a measure of chemotaxis. The data in the following table show that histamine induces a dose-dependent shape change in eosinophils. Histamine receptor (HR) antagonists were used to sort out
 10 which histamine receptor is responsible for the shape change. Antagonists specific for the histamine H₁ receptor (diphenhydramine) or the H₂ receptor (ranatidine) did not alter the histamine-induced shape change. However, a dual H₃/H₄ antagonist (thiopramide) and a specific histamine H₄ receptor
 15 antagonist ((5-Chloro-1*H*-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone, K₁ = 5 nM) inhibited histamine-induced eosinophil shape change with an IC₅₀ of 1.5 and 0.27 μ M, respectively.

Histamine (μ M):	Fold Change				
	10	1	0.1	0.01	0
No HR Antagonist	1.34	1.31	1.21	1.01	1.00
10 μ M H ₄ Antagonist	1.09	1.05	1.05	1.01	1.00
10 μ M Thiop	1.08	1.05	1.01	1.04	1.00
10 μ M Diphen	1.63	1.50	1.18	1.03	1.00
10 μ M Ranat	1.64	1.49	1.21	1.04	1.00

The Inhibition of Eosinophil Chemotaxis by Histamine H₄ Receptor Antagonists

Eosinophil accumulation in sites of allergic reaction is a well-known characteristic of allergic rhinitis and asthma. Eosinophils are purified from human blood with standard methods. Chemotaxis assays are carried out using transwells (Costar, Cambridge, MA) of a pore size 5 μ m coated with 100 μ L of 100 ng/mL human fibronectin (Sigma) for 2 h at room temperature. After removal of the fibronectin, 600 μ L of RPMI with 5% BSA in the presence of histamine (ranging from 1.25–20 μ M) is added to the bottom chamber. To test the various histamine receptor antagonists 10 μ M of the test compounds can be added to the top and bottom chambers. Eosinophils will be added to the top chamber whereas histamine or chemotactic factors will be placed in the lower chamber. The plates are incubated for 3 h at 37 °C. Transwells are removed and the number of cells in the bottom chamber can be counted for 60 s using a flow cytometer, or can be quantitated by using Giemsa staining.

15

The Inhibition of Zymosan-Induced Peritonitis in Mice by Histamine H₄ Receptor Antagonists

It has been demonstrated that histamine H₄ receptor antagonists can block the peritonitis induced by zymosan, which is the insoluble polysaccharide component on the cell wall of *Saccharomyces cerevisiae*. This is commonly used to induce peritonitis in mice and appears to act in a mast cell-dependent manner. Compounds of the present invention can be tested in such a model to demonstrate their use as anti-inflammatory agents. At time 0 mice are given compound or PBS, either s.c. or p.o. Fifteen minutes later each mouse receives 1 mg zymosan A (Sigma) i.p. The mice are sacrificed 4 h later, and the peritoneal cavities are washed with 3 mL of PBS containing 3 mM EDTA. The number of migrated leukocytes is determined by taking an aliquot (100 μ L) of the lavage fluid and diluting 1:10 in Turk's solution (0.01% crystal violet in 3% acetic acid). The samples are then vortexed, and 10 μ L of the stained cell solution is placed in a Neubauer haemocytometer. Differential cell counts are performed using a light microscope (Olympus B061). In view of their chromatic characteristics and their nucleus and cytoplasm appearance, polymorphonuclear leukocytes (PMN; >95% neutrophils) can be easily

20
25
30

identified. Treatment with zymosan increases the number of neutrophils, which is representative of an inflammatory response. Treatment with H₄ receptor antagonist will block this increase.


5 Inhibition of Mast Cell Chemotaxis by H₄ Receptor Antagonist in an Animal Model of Asthma and Allergic Rhinitis

An animal model will be used to test the observation that mast cells accumulate in response to allergic inflammation and that this can be blocked by H₄ receptor antagonists. Compounds of the present invention can be tested
10 in this model to demonstrate their use as treatments for allergic rhinitis or asthma. Mice will be sensitized by intraperitoneal injection of ovalbumin/Alum (10 µg in 0.2ml Al(OH)₃; 2%) on Day 0 and Day 14. On Day 21 through 23 mice will be challenged by PBS or ovalbumin, and sacrificed 24 h after the last challenge on Day 24. A section of the trachea will be removed and fixed in
15 formalin. Paraffin embedding and longitudinal sectioning of tracheas will be performed followed by staining of mast cells with toluidine blue. Alternatively, trachea will be frozen in OCT for frozen sectioning, and mast cells will be identified by IgE staining. Mast cells will be quantified as sub-mucosal or sub-epithelial depending on their location within each tracheal section. Exposure to
20 allergen should increase the number of sub-epithelial mast cells, and this effect will be blocked by H₄ receptor antagonists.


The features and advantages of the invention are apparent to one of ordinary skill in the art. Based on this disclosure, including the summary, detailed description, background, examples, and claims, one of ordinary skill in
25 the art will be able to make modifications and adaptations to various conditions and usages. Publications described herein are incorporated by reference in their entirety. These other embodiments are also within the scope of the invention.

What is claimed is:

1. A compound of formula (I):



5 wherein



Y is O or S;

Z is O or S;

10 n is 1 or 2;

m is 1 or 2;

n + m is 2 or 3;

R¹ is H or C₁₋₆alkyl;

R² is H, F, Cl, Br or C₁₋₆alkyl;

15 R³ and R⁴ are, independently, H, C₁₋₄alkyl, C₃₋₆cycloalkyl,

C₁₋₄alkyl(C₃₋₆cycloalkyl), cyano, -CF₃, -(CO)NR^pR^q, -(CO)OR^r, -CH₂NR^pR^q or -CH₂OR^r; where R^p, R^q and R^r are independently selected from H,

C₁₋₄alkyl, C₃₋₆cycloalkyl, phenyl, -C₁₋₂alkyl(C₃₋₆cycloalkyl), benzyl or phenethyl, or R^p and R^q taken together with the nitrogen to which they are

20 attached, form a 4-7 membered heterocyclic ring with 0 or 1 additional

heteroatoms selected from O, S, NH or NC₁₋₆alkyl, and where any phenyl or alkyl or cycloalkyl moiety of the foregoing is optionally and

independently substituted with between 1 and 3 substituents selected

from C₁₋₃alkyl, halo, hydroxy, amino, and C₁₋₃alkoxy;

25 R⁵ and R⁶ are, independently, H or C₁₋₆alkyl;

R^7 is $-R^a$, $-R^bR^a$, $-R^e-O-R^a$ or $-R^e-N(R^c)(R^d)$, where R^a is H, cyano,
 $-(C=O)N(R^c)(R^d)$, $-C(=NH)(NH_2)$, C_{1-10} alkyl, C_{2-8} alkenyl, C_{3-8} cycloalkyl,
 C_{4-7} heterocyclic radical or phenyl, where the C_{4-7} heterocyclic radical is
 attached at a carbon atom and contains one of O, S, NH or NC_{1-4} alkyl,
 5 and optionally an additional NH or NC_{1-6} alkyl in rings of 5 or 6 or 7
 members, where R^b is C_{1-8} alkylene or C_{2-8} alkenylene, where R^e is
 C_{2-8} alkylene or C_{2-8} alkenylene, where R^c and R^d are each independently
 H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{3-6} cycloalkyl or phenyl, or R^c and R^d taken
 together with the nitrogen to which they are attached, form a 4-7
 10 membered heterocyclic ring with 0 or 1 additional heteroatoms selected
 from O, S, NH or NC_{1-6} alkyl, and where any phenyl or alkyl or cycloalkyl
 moiety of the foregoing is optionally and independently substituted with
 between 1 and 3 substituents selected from C_{1-3} alkyl, halo, hydroxy,
 amino, and C_{1-3} alkoxy;
 15 alternatively, R^7 may be taken together with an adjacent R^4 as well as
 their carbon and nitrogen of attachment to form a 5, 6 or 7 membered
 heterocyclic ring, with 0 or 1 additional heteroatoms selected from O, S,
 NH or NC_{1-6} alkyl, and optionally and independently substituted with
 between 1 and 3 substituents selected from C_{1-3} alkyl, halo, hydroxy,
 20 amino, and C_{1-3} alkoxy;
 R^8 and R^9 are, independently, H, F, Cl, Br, I, C_{1-4} alkyl, C_{1-4} alkoxy,
 $-C_{3-6}$ cycloalkyl, $-OC_{3-6}$ cycloalkyl, $-OCH_2Ph$, $-CF_3$, $-OCF_3$, $-SCF_3$, $-(C=O)R^k$
 (wherein R^k is H, C_{1-4} alkyl, $-OH$, phenyl, benzyl, phenethyl or C_{1-6} alkoxy),
 $-(N-R^t)(C=O)R^k$ (where R^t is H or C_{1-4} alkyl), $-(N-R^t)SO_2C_{1-4}$ alkyl,
 25 $-(S(O)_p)-C_{1-4}$ alkyl (wherein p is 0, 1 or 2), nitro, $-SO_2NR^lR^m$ (wherein R^l
 and R^m are independently selected from H, C_{1-4} alkyl, phenyl, benzyl or
 phenethyl, or R^l and R^m taken together with the nitrogen to which they are
 attached, form a 4-7 membered heterocyclic ring with 0 or 1 additional
 heteroatoms selected from O, S, NH or NC_{1-4} alkyl), $-(C=O)NR^lR^m$, cyano
 30 or phenyl, where any phenyl or alkyl or cycloalkyl moiety of the foregoing
 is optionally and independently substituted with between 1 and 3
 substituents selected from C_{1-3} alkyl, halo, hydroxy, amino, and C_{1-3} alkoxy;

and enantiomers, diastereomers and pharmaceutically acceptable salts and esters thereof,

with the following provisos,


that R^6 adjacent to N must be H where R^4 adjacent to N is other than H,

5 that R^7 is not $-\text{CH}_2\text{CH}_2\text{OH}$; and


that where the core molecule is a 4H-furo, then one of R^4 and R^6 adjacent to N must not be methyl when the other is hydrogen unless R^6 and R^4 are taken together to form a bridging moiety.

2 A pharmaceutical composition containing a compound of formula (I):

10



wherein



15 Y is O or S;

Z is O or S;

n is 1 or 2;

m is 1 or 2;

n + m is 2 or 3;

20 R^1 is H or C_{1-6} alkyl;

R^2 is H, F, Cl, Br or C_{1-6} alkyl;

R^3 and R^4 are, independently, H, C_{1-4} alkyl, C_{3-6} cycloalkyl,

C_{1-4} alkyl(C_{3-6} cycloalkyl), cyano, $-\text{CF}_3$, $-(\text{CO})\text{NR}^p\text{R}^q$, $-(\text{CO})\text{OR}^r$, $-\text{CH}_2\text{NR}^p\text{R}^q$ or $-\text{CH}_2\text{OR}^r$; where R^p , R^q and R^r are independently selected from H,

25 C_{1-4} alkyl, C_{3-6} cycloalkyl, phenyl, $-\text{C}_{1-2}$ alkyl(C_{3-6} cycloalkyl), benzyl or phenethyl, or R^p and R^q taken together with the nitrogen to which they are

attached, form a 4-7 membered heterocyclic ring with 0 or 1 additional heteroatoms selected from O, S, NH or NC₁₋₆alkyl, and where any phenyl or alkyl or cycloalkyl moiety of the foregoing is optionally and independently substituted with between 1 and 3 substituents selected

5 from C₁₋₃alkyl, halo, hydroxy, amino, and C₁₋₃alkoxy;

R⁵ and R⁶ are, independently, H or C₁₋₆alkyl;

R⁷ is -R^a, -R^bR^a, -R^e-O-R^a or -R^e-N(R^c)(R^d), where R^a is H, cyano, -C(=O)N(R^c)(R^d), -C(=NH)(NH₂), C₁₋₁₀alkyl, C₂₋₈alkenyl, C₃₋₈cycloalkyl, C₄₋₇heterocyclic radical or phenyl, where the C₄₋₇heterocyclic radical is

10 attached at a carbon atom and contains one of O, S, NH or NC₁₋₄alkyl, and optionally an additional NH or NC₁₋₆alkyl in rings of 5 or 6 or 7 members, where R^b is C₁₋₈alkylene or C₂₋₈alkenylene, where R^e is C₂₋₈alkylene or C₂₋₈alkenylene, where R^c and R^d are each independently H, C₁₋₄alkyl, C₂₋₄alkenyl, C₃₋₆cycloalkyl or phenyl, or R^c and R^d taken

15 together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring with 0 or 1 additional heteroatoms selected from O, S, NH or NC₁₋₆alkyl, and where any phenyl or alkyl or cycloalkyl moiety of the foregoing is optionally and independently substituted with between 1 and 3 substituents selected from C₁₋₃alkyl, halo, hydroxy,

20 amino, and C₁₋₃alkoxy;

alternatively, R⁷ may be taken together with an adjacent R⁴ as well as their carbon and nitrogen of attachment to form a 5, 6 or 7 membered heterocyclic ring, with 0 or 1 additional heteroatoms selected from O, S, NH or NC₁₋₆alkyl, and optionally and independently substituted with

25 between 1 and 3 substituents selected from C₁₋₃alkyl, halo, hydroxy, amino, and C₁₋₃alkoxy;

R⁸ and R⁹ are, independently, H, F, Cl, Br, I, C₁₋₄alkyl, C₁₋₄alkoxy, -C₃₋₆cycloalkyl, -OC₃₋₆cycloalkyl, -OCH₂Ph, -CF₃, -OCF₃, -SCF₃, -(C=O)R^k (wherein R^k is H, C₁₋₄alkyl, -OH, phenyl, benzyl, phenethyl or C₁₋₆alkoxy),

30 -(N-R^t)(C=O)R^k (where R^t is H or C₁₋₄alkyl), -(N-R^t)SO₂C₁₋₄alkyl, -(S(=O)_p)-C₁₋₄alkyl (wherein p is 0, 1 or 2), nitro, -SO₂NR^lR^m (wherein R^l and R^m are independently selected from H, C₁₋₄alkyl, phenyl, benzyl or phenethyl, or R^l and R^m taken together with the nitrogen to which they are

attached, form a 4-7 membered heterocyclic ring with 0 or 1 additional heteroatoms selected from O, S, NH or NC₁₋₄alkyl), -(C=O)NR^lR^m, cyano or phenyl, where any phenyl or alkyl or cycloalkyl moiety of the foregoing is optionally and independently substituted with between 1 and 3

5 substituents selected from C₁₋₃alkyl, halo, hydroxy, amino, and C₁₋₃alkoxy; and enantiomers, diastereomers and pharmaceutically acceptable salts and esters thereof,


with the following provisos,

that R⁶ adjacent to N must be H where R⁴ adjacent to N is other than H,


10 that R⁷ is not -CH₂CH₂OH; and

that where the core molecule is a 4*H*-furo, then one of R⁴ and R⁶ adjacent to N must not be methyl when the other is hydrogen unless R⁶ and R⁴ are taken together to form a bridging moiety.

3 A method for the treatment or prevention of H₄-mediated diseases and
15 conditions comprising the step of administering to a patient in need of such treatment or prevention a pharmaceutical composition containing an effective amount of a compound of formula (I):



20 wherein



Y is O or S;

Z is O or S;

25 n is 1 or 2;

m is 1 or 2;

$n + m$ is 2 or 3;

R^1 is H or C_{1-6} alkyl;

R^2 is H, F, Cl, Br or C_{1-6} alkyl;

R^3 and R^4 are, independently, H, C_{1-4} alkyl, C_{3-6} cycloalkyl,

- 5 C_{1-4} alkyl(C_{3-6} cycloalkyl), cyano, $-CF_3$, $-(CO)NR^pR^q$, $-(CO)OR^r$, $-CH_2NR^pR^q$ or $-CH_2OR^r$; where R^p , R^q and R^r are independently selected from H, C_{1-4} alkyl, C_{3-6} cycloalkyl, phenyl, $-C_{1-2}$ alkyl(C_{3-6} cycloalkyl), benzyl or phenethyl, or R^p and R^q taken together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring with 0 or 1 additional
- 10 heteroatoms selected from O, S, NH or NC_{1-6} alkyl, and where any phenyl or alkyl or cycloalkyl moiety of the foregoing is optionally and independently substituted with between 1 and 3 substituents selected from C_{1-3} alkyl, halo, hydroxy, amino, and C_{1-3} alkoxy;

R^5 and R^6 are, independently, H or C_{1-6} alkyl;

- 15 R^7 is $-R^a$, $-R^bR^a$, $-R^e-O-R^a$ or $-R^e-N(R^c)(R^d)$, where R^a is H, cyano, $-(C=O)N(R^c)(R^d)$, $-C(=NH)(NH_2)$, C_{1-10} alkyl, C_{2-8} alkenyl, C_{3-8} cycloalkyl, C_{4-7} heterocyclic radical or phenyl, where the C_{4-7} heterocyclic radical is attached at a carbon atom and contains one of O, S, NH or NC_{1-4} alkyl, and optionally an additional NH or NC_{1-6} alkyl in rings of 5 or 6 or 7
- 20 members, where R^b is C_{1-8} alkylene or C_{2-8} alkenylene, where R^e is C_{2-8} alkylene or C_{2-8} alkenylene, where R^c and R^d are each independently H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{3-6} cycloalkyl or phenyl, or R^c and R^d taken together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring with 0 or 1 additional heteroatoms selected
- 25 from O, S, NH or NC_{1-6} alkyl, and where any phenyl or alkyl or cycloalkyl moiety of the foregoing is optionally and independently substituted with between 1 and 3 substituents selected from C_{1-3} alkyl, halo, hydroxy, amino, and C_{1-3} alkoxy;
- alternatively, R^7 may be taken together with an adjacent R^4 as well as
- 30 their carbon and nitrogen of attachment to form a 5, 6 or 7 membered heterocyclic ring, with 0 or 1 additional heteroatoms selected from O, S, NH or NC_{1-6} alkyl, and optionally and independently substituted with

between 1 and 3 substituents selected from C₁₋₃alkyl, halo, hydroxy, amino, and C₁₋₃alkoxy;

R⁸ and R⁹ are, independently, H, F, Cl, Br, I, C₁₋₄alkyl, C₁₋₄alkoxy,

5 -C₃₋₆cycloalkyl, -OC₃₋₆cycloalkyl, -OCH₂Ph, -CF₃, -OCF₃, -SCF₃, -(C=O)R^k
(wherein R^k is H, C₁₋₄alkyl, -OH, phenyl, benzyl, phenethyl or C₁₋₆alkoxy),
-(N-R^t)(C=O)R^k (where R^t is H or C₁₋₄alkyl), -(N-R^t)SO₂C₁₋₄alkyl,
-(S(=O)_p)-C₁₋₄alkyl (wherein p is 0, 1 or 2), nitro, -SO₂NR^lR^m (wherein R^l
and R^m are independently selected from H, C₁₋₄alkyl, phenyl, benzyl or
phenethyl, or R^l and R^m taken together with the nitrogen to which they are
10 attached, form a 4-7 membered heterocyclic ring with 0 or 1 additional
heteroatoms selected from O, S, NH or NC₁₋₄alkyl), -(C=O)NR^lR^m, cyano
or phenyl, where any phenyl or alkyl or cycloalkyl moiety of the foregoing
is optionally and independently substituted with between 1 and 3
substituents selected from C₁₋₃alkyl, halo, hydroxy, amino, and C₁₋₃alkoxy;

15 and enantiomers, diastereomers and pharmaceutically acceptable salts and
esters thereof,

with the following provisos,

that R⁶ adjacent to N must be H where R⁴ adjacent to N is other than H,

that R⁷ is not -CH₂CH₂OH; and

20 that where the core molecule is a 4*H*-furo, then one of R⁴ and R⁶ adjacent to N
must not be methyl when the other is hydrogen unless R⁶ and R⁴ are taken
together to form a bridging moiety.